Contineum Therapeutics, Inc. (CTNM)
| Market Cap | 485.37M +306.1% |
| Revenue (ttm) | n/a |
| Net Income | -59.98M |
| EPS | -2.17 |
| Shares Out | 37.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 159,691 |
| Open | 12.41 |
| Previous Close | 12.41 |
| Day's Range | 12.41 - 13.05 |
| 52-Week Range | 3.35 - 16.33 |
| Beta | 1.38 |
| Analysts | Buy |
| Price Target | 19.00 (+46.15%) |
| Earnings Date | May 13, 2026 |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitt... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CTNM stock is "Buy." The 12-month stock price target is $19.0, which is an increase of 46.15% from the latest price.
News
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing two clinical-stage assets, PIPE-791 and PIPE-307, with a focus on pulmonary fibrosis and MDD. PIPE-791 differentiates through once-daily dosing, high receptor occupancy, and a strong safety profile, while PIPE-307 is partnered with J&J for rapid-onset MDD therapy. Key catalysts this year include PIPE-791 pain data, J&J’s MDD results, and BMS’s phase III readout.
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Significant clinical progress was made with four studies, including advancing PIPE-791 for IPF and chronic pain. PIPE-791 differentiates through high receptor occupancy and once-daily dosing, targeting a large unmet need in IPF. Key catalysts include pain study data and BMS’s phase three results.
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value
Contineum Therapeutics, Inc. (NASDAQ: CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS).
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Transcript: Baird Global Healthcare Conference 2025
Two clinical-stage assets target neuroscience and immunology, with PIPE-791 advancing in IPF and pain, and PIPE-307 in MS and MDD via a J&J partnership. Key data readouts are expected this year and next, with strong patent protection and cash runway through 2027.
Contineum Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
The conference highlighted a robust clinical pipeline with near-term data catalysts for two key assets targeting IPF, MS, and depression. PIPE-791 and PIPE-307 are positioned for differentiation through optimized dosing, strong partnerships, and focus on unmet needs, with multiple clinical readouts expected in the next year.
Contineum Therapeutics Transcript: Cantor Global Healthcare Conference 2025
The company is advancing two clinical-stage assets, PIPE-791 and PIPE-307, targeting significant unmet needs in IPF, MS, and chronic pain. A global phase 2 IPF study for PIPE-791 will launch in Q4, with key data readouts expected over the next year.
Contineum Therapeutics to Present at September Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025
Recent advances in LPA1 antagonist programs address prior safety issues and optimize dosing, with key PET data for type 791 expected soon. The pipeline expands into MS and pain, while the muscarinic program progresses in MS and depression through a J&J partnership. Strong IP and funding support continued development.
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Transcript: Stifel 2025 Virtual CNS Forum
The company is advancing a robust clinical pipeline in neuroscience and immunology, with seven studies planned for 2025 and key data readouts expected this year for MS and depression programs. LPA1-targeted therapies are progressing in MS, IPF, and pain, and funding is secured through 2027.
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...